CE: 1.0 credit/hour

Disclosures:

• Sandy Kurtin and Heather Koniarczyk have no relevant financial relationships to disclose.
• Andrea Edwards has served on the advisory board for McKesson and as a consultant for AstraZeneca.
• Lisa Hwa has served on the advisory boards for Akcea, GSK, and Janssen.
• Erin Pierce has served on the speakers bureaus for Astellas, Exelixis, Helsinn Therapeutics, Janssen, Merck, Pfizer, and Sanofi; on the advisory boards for Eisai, Exelixis, Janssen, and Seagen; and as a consultant for Exelixis and Janssen.

Learning Objectives:

• Describe the scope and state of the hematology/oncology (heme/onc) advanced practitioner (AP) workforce
• Discuss productivity metrics applied to heme/onc advanced practice
• Discuss the role of the heme/onc AP in leveraging quality improvement to improve practice
• Describe the role of the heme/onc AP in clinical research
• Discuss appropriate compensation for heme/onc APs
• Discuss leadership strategies for recruitment and retention of heme/onc APs and AP leaders

CE: 0.75 credit/hour, including .50 pharmacology credit

Disclosures:

• Mary Morgan has no relevant financial relationships to disclose.
• Tammy Triglianos has served on the advisory board for Pfizer. Relevant financial relationships have been mitigated.

Learning Objectives:

• Identify appropriate screening strategies to improve uptake of colorectal cancer screening as recommended in current guidelines.
• Assess the potential benefits and risks of current treatment options for patients with colorectal cancer.
• Apply current evidence-based clinical practice guidelines and patient preferences to inform clinical practice and improve treatment outcomes for patients with colorectal cancer.

CE: 0.75 credit/hour, including 0.5 pharmacology credit

Disclosures:

• Amber Koehler has participated in advisory boards for AbbVie, Janssen, and AstraZeneca.
• Josie Montegaard has participated in advisory boards for AbbVie and Beigene.

Learning Objectives:

• List currently recommended agents for frontline therapy in chronic lymphocytic leukemia (CLL)
• Outline key patient characteristics that may help in choice of frontline therapy for treatment-naive CLL
• Consider patient and lifestyle factors when selecting a treatment course
• Develop a management plan for common adverse events that may occur in patients with CLL on frontline therapy

CE: 1.0 credit/hour, including 0.75 pharmacology credit

Disclosures:

• Tajuana Bradley has served on speakers bureaus for ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Coherus, G1 Therapeutics, Puma Biotechnology, and Seagen.
• Beth Sandy has served on the speakers bureaus for Amgen, AstraZeneca, Jazz Pharmaceuticals, Lilly, Merck, and Takeda, and as a consultant for AbbVie and Janssen.

Learning Objectives:

• Evaluate pivotal clinical trials leading to recent FDA approvals of new molecular targeted treatment options for patients with metastatic non-small cell lung cancer (NSCLC), and related updates to clinical practice guidelines.
• Differentiate recently validated predictive and prognostic biomarkers and their clinical relevance for treating patients with mNSCLC.
• Integrate evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with mNSCLC.

CE: 1.0 credit/hourr, including 0.75 pharmacology credit

Disclosures:

• Anecita Fadol has no relevant financial relationships to disclose.

Learning Objectives:

• Identify the most common anticancer agents with potential cardiotoxicity
• Describe the common risk factors and links between cancer, oncology treatments and cardiovascular disease
• Explain the management of common cancer therapy–related cardiac dysfunction in patients with cancer and survivors

CE: 1.0 credit/hour

Matthew Zachary is Founder of the award-winning nonprofit Stupid Cancer, and known for starting the young adult cancer movement in 2007. He was christened the "Podfather of Healthcare" for hosting The Stupid Cancer Show, the first streaming healthcare podcast before podcasts. Matthew is also co-founder and chair of OffScrip Health, a prestige documentary podcast studio where he hosts "Out of Patients with Matthew Zachary," a Top-10 Healthcare Podcast.

A provocateur with an authentic passion for disruption, Matthew shared his lived experience of personal empowerment and self-advocacy and his divergent thoughts on challenging conventional wisdom about survivorship with attendees at JADPRO Live.

Learning Objectives:

• Demonstrate a broader understanding of the human aspects of cancer
• Understand how to assist patients in recognizing medically sound websites from those less reputable
• Describe the impact of media on the patient with cancer
• Discuss the stigma and social discomforts faced by patients with cancer and describe methods of psychosocial support

CE: 0.75 credit/hour, including 0.75 pharmacology credit

Disclosures:

• Beth Finley-Oliver has no relevant financial relationships to disclose.
• Rachid Baz has received research support from AbbVie, BMS, Janssen, Karyopharm, and Regeneron; has served on the advisory boards for Janssen and BMS; and has received honoraria from HIKMA Cancer Network (CME presentation), and GSK (member of response assessment committee).

Learning Objectives:

• Select appropriate treatment regimens for newly diagnosed multiple myeloma based on current guidelines, patient characteristics, and potential benefits and risks.
• Apply knowledge of treatment options, risks and benefits, and practice guidelines to select specific treatment regimens for patients with relapsed or refractory multiple myeloma.
• Provide comprehensive patient-centric care that accounts for the preferences, treatment goals, side effects, and supportive care needs of patients with multiple myeloma.

CE: 0.75 credit/hour, including 0.25 pharmacology credit

Disclosures:

• Lorraine Drapek has no relevant financial relationships to disclose.
  
• Katie Bukolt has no relevant financial relationships to disclose.

Learning Objectives:

• Discuss the history of radiation oncology, as well as current treatment and future trends
• Plan strategies to manage acute and long-term effects of radiation treatment
• Identify at-risk populations and problem-solving management interventions.

Announcement and recognition of APSHO members who have achieved the Fellow of Advanced Practice in Oncology (FAPO) designation in 2023. Join us in celebration and appreciation of their commitment, engagement, and inspiring leadership as advanced practitioners.

For more information on the Fellow of Advanced Practice in Oncology (FAPO) designation visit APSHO.org

Announcement and presentation of the Mary Pazdur Award for Excellence in Advanced Practice in Oncology, an award recognizing and honoring a member of the Advanced Practitioner Society for Hematology and Oncology (APSHO) who demonstrates exemplary leadership and makes outstanding contributions in areas of clinical practice, research, education, collaboration and mentorship.

To learn more about the Mary Pazdur award, visit marypazduraward.com

CE: 0.50 credit/hour

Dr. Haviland presents on individualized care for LGBTQI+ patients and the importance of understanding sexual orientation and gender identity in her lecture, "Health Equity: Cancer Care for LGBTQI+ Populations."

Disclosures:

• Kelly Haviland has no relevant financial relationships to disclose.

Learning Objectives:

• Discuss LGBTQI+ healthcare and cancer care disparities
• Describe clinical tools useful for care of LGBTQI+ patients with cancer

CE: 1.00 credit/hour, including 1.00 pharmacology credit

Disclosures:

• Lisa Holle has no relevant financial relationships to disclose.

Learning Objectives:

• Review the approved label indications of new drugs and biologics in hematology/oncology.
• Describe the mechanisms of action for recently approved drugs and biologics in hematology/oncology.
• Develop plans to monitor and manage side effects associated with administration of newly approved drugs and biologics in hematology/oncology.

CE: 1.00 credit/hour, including 0.25 pharmacology credit

Disclosures:

• Steven H. Wei has no relevant financial relationships to disclose.

Learning Objectives:

• Define the field of surgical oncology and describe the goals of cancer surgery, including palliation and curative intent.
• Describe the role of surgery in the multidisciplinary management of patients with solid tumors, including combined modality treatments for common cancers.
• Discuss surgical indications in patients with advanced metastatic disease, including the risks, benefits, and alternatives of treatment.
• Describe the role of advanced practitioners in the field of surgical oncology

CE: 1.0 credit/hour, including 1.0 pharmacology credit

Disclosures:

• Stephanie L. Graff has served on advisory boards for Seagen, Novartis, Pfizer, Lilly, Daiichi Sankyo, AstraZeneca, Genentech, Stemline; and has stock ownership for HCA Healthcare.
• Christine McGinn and Jeannie Showalter have no relevant financial relationships to disclose.

Learning Objectives:

• Discuss recent FDA approvals and practice guideline updates related to advancing care for patients with metastatic HER2-overexpressing breast cancer.
• Interpret the increased clinical relevance of the new “HER2-low” category of HER2 expression for the treatment of patients with metastatic breast cancer.
• Apply evidence-based best practices when monitoring and managing adverse events associated with novel HER2-targeted agents when caring for patients with metastatic breast cancer.

CE: 1.0 credit/hour, including 0.25 pharmacology credit

Disclosures:

• Peter Hakos owns stock in AbbVie and Pfizer.

Learning Objectives:

• Identify anemia, thrombocytopenia, and neutropenia and describe the workup of each process
• Develop a differential diagnosis based on the cytopenic workup
• List key elements of a treatment plan for common causes of cytopenias in the benign hematology setting

CE: 1.0 credit/hour, including 0.75 pharmacology credit

Disclosures:

• Grace Baek has no relevant financial relationships to disclose.
• Andrew Guinigundo has served as a consultant for Amgen, Jazz, and Pharmacosmos; and on speakers bureaus for Amgen, Astellas, GSK, and Pfizer.

Learning Objectives:

• Study recently approved precision-targeted cancer therapies and their corresponding biomarkers.
• Evaluate results of companion diagnostic tests to select appropriate treatments
• Follow evidence-based testing guidelines to optimize care for patients with cancer

CE: 1.0 credit/hour, including 1.0 pharmacology credit

Disclosures:

• Stephanie Daniels has no relevant financial relationships to disclose.
• Shreya Desai has no relevant financial relationships to disclose..

Learning Objectives:

• Describe the structure and signaling through chimeric antigen receptor (CAR)
• Identify CAR-T products and their eligibility requirements
• Monitor for and manage toxicities associated with CAR-T therapy, with a focus on long-term management in the community setting
• Recognize future advances in cellular therapy

CE: 1.0 credit/hour, including 1.0 pharmacology credit

Disclosures:

• Sandra Cuellar reports that she receives honoraria for serving on speaker bureaus from Mirati and Genentech.

Learning Objectives:

• Identify new investigational therapeutic agents currently being evaluated in the hematology/oncology pipeline.
• Describe the pharmacology of novel investigational therapeutics currently under development.
• Discuss literature supporting the ongoing evaluation of emerging therapeutic agents.

CE: 1.0 credit/hour

Disclosures:

• Adria Myers has no relevant financial relationships to disclose.
• Holly Chitwood has served on advisory boards for Gilead Oncology, and on the speakers bureau for Astra Zeneca.

Learning Objectives:

• Define circulating tumor DNA (ctDNA) and appraise evolving technology
• Describe current ctDNA application with solid tumors and emerging indications in practice with an overview of commercially available assays
• Discuss the advanced practice provider’s role in ctDNA utilization
• Identify emerging clinical trial data and evolving recommendations for ctDNA utilization

CE: 1.0 credit/hour, including 1.0 pharmacology credit

Disclosures:

Rebecca Rezac has no relevant financial relationships to disclose.

Learning Objectives:

• Review the approved label indications of new drugs and biologics in hematology/oncology
• Describe the mechanisms of action for recently approved drugs and biologics in hematology/oncology
• Develop plans to monitor and manage side effects associated with administration of newly approved drugs and biologics in hematology/oncology

CE: 1.0 credit/hour, including 0.75 pharmacology credit

Disclosures:

• Veronica Brady discloses a financial relationship with Diathrive Health.

Learning Objectives:

• Recognize the most common endocrine toxicities seen among cancer patients.
• Identify the medications most associated with endocrine toxicities.
• Describe patient and family education needs related to the most common endocrine toxicities.

CE: 1.0 credit/hour, including 0.5 pharmacology credit

Disclosures:

• Kristin Daly has no relevant financial relationships to disclose.
• Kathryn Slane has no relevant financial relationships to disclose.

Learning Objectives:

• Recall current standard-of-care treatments in head and neck squamous cell carcinoma (HNSCC)
• Discuss clinical trials involving immunotherapy in both curative and palliative settings for HNSCC non-nasopharyngeal cancers (non-NPC)
• Identify predictive and prognostic biomarkers with clinical implications in head and neck cancers
• Anticipate side effects commonly associated with these various therapies

CE: 0.75 credit/hour, including 0.5 pharmacology credit

Disclosures:

• Jessica Deinert has no relevant financial relationships to disclose.
• Leah Shaw has no relevant financial relationships to disclose.

Learning Objectives:

• Discuss best practices in diagnosis, classification, and management of patients with prostate cancer.
• Select appropriate therapies for the treatment of prostate cancer based on patient characteristics, treatment goals, and potential risks and benefits.
• Provide patient-centric care and support to patients with prostate cancer by engaging in shared decision making and managing side effects and complications of treatment.

CE: 0.75 credit/hour

Disclosures:

• Andrew Guinigundo has served as a consultant for Amgen, Jazz, and Pharmacosmos; and on speakers bureaus for Amgen, Astellas, GSK, and Pfizer.

Learning Objectives:

• Review the importance of biomarker testing in oncology patients, primarily in the solid tumor setting
• Describe racial, LGBTQ+, and socioeconomic inequities that impact biomarker testing rates
• Discuss ways that oncology advanced practitioners can minimize the impact of racial, LBGTQ+, and socioeconomic inequities on biomarker testing in their own practices

CE: 1.0 credit/hour

Disclosures:

Judy Knudson has no relevant financial relationships to disclose.
Jeanne Lee has no relevant financial relationships to disclose.

Learning Objectives:

• Communicate effectively with patients and family members about hospice support as a potential plan of care
• Address family's wishes when they ask healthcare providers to withhold certain medical information from the patient
• Describe how having a patient's medical power of attorney advance directive is often necessary for determining the plan of care
• Redefine "hope" by helping patients and family members reframe goals of care as the patient's medical situation changes